Department of Dermatology
Letter to the Editor
Dermatology | Skin and Connective Tissue Diseases
To the Editor: Vitiligo is a chronic autoimmune disease resulting in patches of depigmented skin and reduced quality of life. In a randomized, dose-ranging phase 2 study (NCT03099304) in 157 adult patients, the Janus kinase (JAK) 1/JAK2 inhibitor ruxolitinib cream produced substantial repigmentation of facial and total body vitiligo lesions after 24 weeks, with continued improvement through week 52, and was well tolerated.3 Here, we present treatment response subanalyses from the phase 2 trial.
Rights and Permissions
Copyright 2021 by the American Academy of Dermatology, Inc. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/.
DOI of Published Version
Hamzavi I, Rosmarin D, Harris JE, Pandya AG, Lebwohl M, Gottlieb AB, Butler K, Kuo FI, Sun K, Grimes P. Efficacy of ruxolitinib cream in vitiligo by patient characteristics and affected body areas: Descriptive subgroup analyses from a phase 2, randomized, double-blind trial. J Am Acad Dermatol. 2021 Jun 2:S0190-9622(21)01043-4. doi: 10.1016/j.jaad.2021.05.047. Epub ahead of print. PMID: 34089797. Link to article on publisher's site
Journal of the American Academy of Dermatology
Hamzavi I, Rosmarin D, Harris JE, Pandya AG, Lebwohl M, Gottlieb AB, Butler K, Kuo FI, Sun K, Grimes P. (2021). Efficacy of ruxolitinib cream in vitiligo by patient characteristics and affected body areas: Descriptive subgroup analyses from a phase 2, randomized, double-blind trial. Open Access Publications by UMass Chan Authors. https://doi.org/10.1016/j.jaad.2021.05.047. Retrieved from https://escholarship.umassmed.edu/oapubs/4792
Creative Commons License
This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 4.0 License.